PL1559431T3 - Kompozycja farmaceutyczna dla pochodnych peptydu trombiny - Google Patents

Kompozycja farmaceutyczna dla pochodnych peptydu trombiny

Info

Publication number
PL1559431T3
PL1559431T3 PL04258191T PL04258191T PL1559431T3 PL 1559431 T3 PL1559431 T3 PL 1559431T3 PL 04258191 T PL04258191 T PL 04258191T PL 04258191 T PL04258191 T PL 04258191T PL 1559431 T3 PL1559431 T3 PL 1559431T3
Authority
PL
Poland
Prior art keywords
pharmaceutical composition
thrombin peptide
peptide derivatives
thrombin
disclosed
Prior art date
Application number
PL04258191T
Other languages
English (en)
Polish (pl)
Inventor
David M Hobson
Roger S Crowther
Darrell H Carney
Andrew Po Kwan Tang
Original Assignee
Orthologic Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orthologic Corp filed Critical Orthologic Corp
Publication of PL1559431T3 publication Critical patent/PL1559431T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4833—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
PL04258191T 2003-12-31 2004-12-30 Kompozycja farmaceutyczna dla pochodnych peptydu trombiny PL1559431T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53373003P 2003-12-31 2003-12-31
EP04258191A EP1559431B1 (en) 2003-12-31 2004-12-30 Pharmaceutical composition for thrombin peptide derivatives

Publications (1)

Publication Number Publication Date
PL1559431T3 true PL1559431T3 (pl) 2007-10-31

Family

ID=34652502

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04258191T PL1559431T3 (pl) 2003-12-31 2004-12-30 Kompozycja farmaceutyczna dla pochodnych peptydu trombiny

Country Status (13)

Country Link
US (2) US7291596B2 (https=)
EP (1) EP1559431B1 (https=)
JP (1) JP5044829B2 (https=)
CN (1) CN1913917B (https=)
AT (1) ATE357928T1 (https=)
AU (1) AU2004312090B2 (https=)
CA (1) CA2551525C (https=)
DE (1) DE602004005564T2 (https=)
DK (1) DK1559431T3 (https=)
ES (1) ES2287660T3 (https=)
PL (1) PL1559431T3 (https=)
PT (1) PT1559431E (https=)
WO (1) WO2005065706A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60313982T2 (de) * 2002-07-02 2008-01-17 Orthologic Corp., Tempe Dimere von thrombinpeptidderivaten
EP3067047B1 (en) 2005-12-08 2022-04-20 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
JP2010504336A (ja) * 2006-09-22 2010-02-12 オーソロジック コーポレイション 血管内皮機能不全を治療する方法
US8227412B2 (en) * 2007-03-29 2012-07-24 Tsopanoglou Nikos E Bioactive parstatin peptides and methods of use
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
CA2722621A1 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Thrombin derived peptides for smooth muscle relaxation
US20110105400A1 (en) * 2008-03-26 2011-05-05 Orthologic Corp. Methods for treating acute myocardial infarction
EP2280722A2 (en) * 2008-03-26 2011-02-09 Orthologic Corp. Method of treating degenerative diseases
WO2009120307A2 (en) * 2008-03-26 2009-10-01 Orthologic Corp. Method of treating peripheral arterial disease
US20110319340A1 (en) * 2008-09-19 2011-12-29 The Board Of Regents, The University Of Texas System Methods for treating cancer
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
WO2011106222A2 (en) 2010-02-23 2011-09-01 Corning Incorporated Modified substrates for protection of peptide-immobilized surfaces from gamma radiation degradation
US10124066B2 (en) * 2012-11-29 2018-11-13 Insmed Incorporated Stabilized vancomycin formulations
BR112016007382B1 (pt) * 2013-10-03 2021-12-21 Luis Alberto Améstica Salazar Composição biocida de resinas que compreendem uma ou mais resinas selecionadas de resinas mf, uf, pf, muf e fenólicas; e mais de um sal de cobre solúvel
LT3466432T (lt) 2014-05-15 2020-12-28 Insmed Incorporated Būdai, skirti plaučių netuberkuliozinėms mikobakterinėms infekcijoms gydyti
US10220078B2 (en) 2014-06-11 2019-03-05 The Board Of Regents Of The University Of Texas System Methods of using thrombin derivatives to treat medulloblastoma
CN105879010A (zh) * 2015-01-17 2016-08-24 内蒙古天奇生物科技有限公司 一种能促进创伤愈合减轻创后瘢痕的多肽组合物及其制备方法
EP3773505B1 (en) 2018-03-30 2026-04-29 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
JP7449275B2 (ja) 2018-05-02 2024-03-13 インスメッド インコーポレイテッド リポソーム薬物製剤の製造方法
EP3952991A4 (en) * 2019-04-12 2023-08-09 Affirmed Pharma, LLC RUSALATIDE ACETATE COMPOSITIONS
JP2023139750A (ja) * 2022-03-22 2023-10-04 株式会社東芝 抗酸化剤を用いたｆｅｔセンサ

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3019612A1 (de) * 1980-05-22 1981-11-26 Boehringer Mannheim Gmbh, 6800 Mannheim Stabilisiertes thrombinpraeparat
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
JP2000229882A (ja) * 1998-12-10 2000-08-22 Sankyo Co Ltd 修飾シクロデキストリン含有トロンビン水性液剤
GB9930768D0 (en) 1999-12-29 2000-02-16 Pfizer Ltd Composition
TWI257307B (en) 2000-07-12 2006-07-01 Orthologic Corp Pharmaceutical composition for cardiac tissue repair
ATE254925T1 (de) * 2000-07-19 2003-12-15 Univ Texas Stimulierung des knochenwachstums mit peptidderivaten von thrombin
AU7356101A (en) * 2000-07-20 2002-02-05 Univ Texas Stimulation of cartilage growth with agonists of the non-proteolytically activated thrombin receptor
AU2002223802A1 (en) * 2000-11-17 2002-05-27 Warner-Lambert Company Llc Treatment of sexual dysfunction with non peptide bombesin receptor antagonists
WO2002074806A2 (en) * 2001-02-27 2002-09-26 Maxygen Aps New interferon beta-like molecules
ES2271216T3 (es) 2001-07-27 2007-04-16 Orthologic Corp. Uso de los peptidos derivados de la trombina para la terapia de las ulceras dermicas cronicas.
ATE504311T1 (de) 2002-01-16 2011-04-15 Capstone Therapeutics Corp Thrombin-derivierten peptiden zur förderung von herzgewebsreparatur
JP2005519067A (ja) 2002-01-17 2005-06-30 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム トロンビンペプチド誘導体を用いた骨成長および軟骨形成の刺激
WO2003092731A1 (en) * 2002-05-03 2003-11-13 Novo Nordisk A/S Stabilised solid compositions of modified factor vii
DE60313982T2 (de) 2002-07-02 2008-01-17 Orthologic Corp., Tempe Dimere von thrombinpeptidderivaten
AU2003256343B2 (en) * 2002-07-02 2006-12-21 Orthologic Corp. Thrombin peptide derivatives

Also Published As

Publication number Publication date
AU2004312090B2 (en) 2008-08-14
JP5044829B2 (ja) 2012-10-10
CN1913917A (zh) 2007-02-14
EP1559431A1 (en) 2005-08-03
EP1559431B1 (en) 2007-03-28
CA2551525A1 (en) 2005-07-21
PT1559431E (pt) 2007-07-02
AU2004312090A1 (en) 2005-07-21
DE602004005564D1 (de) 2007-05-10
US20050203017A1 (en) 2005-09-15
HK1080390A1 (en) 2006-04-28
WO2005065706A1 (en) 2005-07-21
DE602004005564T2 (de) 2007-12-13
ES2287660T3 (es) 2007-12-16
DK1559431T3 (da) 2007-07-30
JP2007518724A (ja) 2007-07-12
ATE357928T1 (de) 2007-04-15
US7875588B2 (en) 2011-01-25
CN1913917B (zh) 2012-02-01
US20090054343A1 (en) 2009-02-26
CA2551525C (en) 2013-02-19
US7291596B2 (en) 2007-11-06

Similar Documents

Publication Publication Date Title
PL1559431T3 (pl) Kompozycja farmaceutyczna dla pochodnych peptydu trombiny
ATE519486T1 (de) Pharmazeutische zusammensetzung mit einem monoamin-neurotransmitter-wiederaufnahmehemmer und einem acetylcholinesterase-hemmer
IL176452A0 (en) Effervescent oral opiate dosage form
NO20062504L (no) Sammensetninger og doseringsformer for forbedret absorpsjon
WO2003072195A3 (en) Method for administering glp-1 molecules
NO20013469L (no) Fremgangsmåter for glukagonsuppresjon
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
WO2000050046A8 (en) Stabilized oral pharmaceutical composition containing iodide and iodate and method
WO2004000354A3 (en) Method of treating the syndrome of lipodystrophy
AU2003246978A1 (en) Pharmaceutical compositions comprising cyclosporin for oral administration
WO2005084296A3 (en) Fused tricyclic compounds as inhibitors of 17beta-hydroxysteroid dehydrogernase 3
HK1045113A1 (zh) 給予固定的曲馬朵和雙氯酚酸組合的口服給藥形式
WO2004032866A3 (en) Therapeutic formulations
IL161834A0 (en) Pharmaceutical compositions and methods for administering ep2 receptor selective agonists
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
CO5261595A1 (es) Composiciones farmaceuticas que contienen una combinacion de salmeterol e ipratropium
WO2004041190A3 (en) Composition for the treatment of macular degenration
AU2003290015A1 (en) Mastitis treatment
IL166596A0 (en) Salt of morphine-6-glucoronide
WO2005048993A3 (en) Minimization of drug oxidation in drug irradiated excipients formulations
AU2003251643A1 (en) Pharmaceutical compositions containing keto-acids for endoperitoneal administration
EP1064948A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
EP1099446A3 (en) Combination treatment for depression and anxiety containing a CNS-penetrant NK-1 receptor antagonist and an antidepressant or anxiolytic agent
DK1061938T3 (da) Orale sammensætninger med cytotoksiske proteiner i lav dosis
WO2005062874A3 (en) Compounds and compositions for delivering active agents